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ABSTRACT
Background and Significance: Prior studies have indicated that early chronic low-level lead
exposure may be associated with adverse effects on motor and cognitive functions. The
mechanisms by which low-level lead affects brain function are unknown. Objectives: The
current study aimed to (1) determine whether early chronic low-level lead exposure altered the
expression of pro- or ant-inflammatory cytokines and markers of oxidative stress in mouse
brain studied at two ages, pre-adolescence (PND 28) and early adulthood (PND 40); and (2) in
the same pre-adolescent and early adulthood mice, compare and contrast the levels of pro- or
ant-inflammatory markers in three brain regions including anterior cerebrum, posterior
cerebrum and cerebellum. Hypothesis: We hypothesized that early chronic exposure to lowlevel lead triggers abnormal expression of pro- or ant-inflammatory markers consistent with an
inflammatory response and oxidative stress in younger and older mice; and that posterior
cerebrum would be more susceptible to the effects of chronic low-level lead than anterior
cerebrum and cerebellum. Methods: Two studies were conducted one in 28 day and one in 40
day old C57BL/6J mice. For each study, mice were assigned to one of three experimental
groups including a control group (no lead exposure), a low dose group (exposed to 40 ppm lead
acetate), and a high dose group (exposed to 230 ppm lead acetate). Mice were exposed to lead
acetate (99.4% pure) via dams’ drinking water from birth until weaning. The gene expression
levels of four pro-inflammatory markers (TNF-α, IFN-γ, IL-6, iNOS), two immune-suppressive
markers (IL-10 and Hmox-1) and an oxidative stress indicator GPR-78 were measured in
homogenized brain sections from anterior cerebrum, posterior cerebrum and cerebellum using
qRT-PCR. These markers were selected because they have roles in brain development and
v

inflammatory responses (Bauer, Kerr, & Patterson, 2007; Ahamed & Siddiqui, 2007; Anthony &
Campbell, 2002; Bokara, et al., 2008; Cabell, et al., 2004; Deverman & Patterson, 2009;
Gastaldello Moreira, de Magalhaes Rosa, Moraes Barros, Vassilieff, & Vassillieff, 2001) Results:
There were no statistically significant differences observed in pre-adolescent mice. Young adult
lead-exposed mice had significant differences in genetic expression of TNF-α, Hmox-1, and GRP78. Lowest level lead exposure caused a statistically significant increase in genetic expression
of TNF-α and Hmox-1 in the low dose group when compared to the control group. Conclusions:
A mixed inflammatory response is activated due to chronic exposure to low-level lead in young
adult mice. Additional studies are needed to further define the role of chronic low level lead
exposure in interfering with normal brain function.
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CHAPTER I: BACKGROUND AND SIGNIFICANCE
The problem of lead exposure has been a topic of public health concern and controversy
for many years. The use of lead throughout history has created multiple means of exposure
throughout the world (Tong, von Schirnding, & Prapamontol, 2000). Lead has been used as an
additive in smelting products, gasoline, household paint, plumbing, pottery, glass, and paint
used to decorate children’s toys and many other readily available items. Though the use of lead
in gasoline, paint, and other items has been significantly reduced or banned in the United
States (Agency for Toxic Substances and Disease Registry, 2010), lead continues to be an
ubiquitous contaminant in the environment and a source for chronic low level exposure in
children. Common sources of chronic low level lead exposure in children are drinking water,
industry, residual lead dust from leaded gasoline combustion, low-income housing units, and
pre-1950’s housing units (Tong, von Schirnding, & Prapamontol, 2000).
Despite the Environmental Protection Agency’s regulations requiring that lead traces in
potable water be below 15 ppb (U.S. Environmental Protection Agency, 2009), individuals living
in older U.S. homes may be exposed to lead through tap water as it is transported to the home
via older plumbing systems that may contain and release lead into the water (Brown &
Margolis, 2012). Studies have found that the amount of lead released from pipes into drinking
water varies and is dependent on the type of water treatment used (Edwards & Dudi, 2004;
Miranda, Kim, Hull, Paul, & Overstreet Galeano, 2007). In Washington D.C., water treatment
was changed from free chlorine to chloramine in the year 2000 which caused an increase of
lead released from pipes and higher incidence of Blood Lead Levels (BLLs) above 5 μg/dL
(Centers for Disease Control and Prevention, 2004). The change in water treatment also
1

increased the incidence of BLLs above 10 μg/dL in children aged less than 1.3 years (Edwards,
Triantafyllidou, & Best, 2009). BLL is used to measure the amount of lead in a person’s body at
the time of blood collection. The BLL of concern has been reduced from 60 μg/dL in 1960
(Centers for Disease Control and Prevention, 2007) to the current reference level of 5 μg/dL
(Centers for Disease Control and Prevention, 2007; Centers for Disease Control and Prevention,
2014). It has been estimated that approximately one-half million children, aged 1-5 years old,
have BLLs above the current “reference level” of 5 μg/dL (Centers for Disease Control and
Prevention, 2014).
Despite these findings, the correlation of elevated BLLs in the population and water lead
level has been inconsistent. A study that attempted to model child BLLs from leadcontaminated water found that water lead levels at 10-15 times above the recommended
threshold set by the Environmental Protection Agency (>20 ppb) – were unlikely to increase
incidence of BLLs above 10 μg/dL (Sathyanarayana, Beaudet, Omri, & Karr, 2006). Studies on
water lead exposures however do not tend to report the incidence of child BLLs below current
thresholds.
Industrial processes and the use of gasoline containing tetraethyl lead have released
lead into the environment for many years resulting in a disproportionate accumulation of lead
in various regions across the United States. Industries often use methods, such as smelting, to
synthesize materials that contain lead. Two studies conducted in border regions along the
U.S./Mexico border where smelters were located found that increased BLLs in children were
associated with the children’s home proximity to the smelters and one of the studies found that
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lead traces >20ppb were still found years after the smelter had ceased operation (Diaz-Barriga,
et al., 1997; Carriazales, et al., 2006).
Methods for measuring lead hazards in the environment include monitoring lead
concentrations in the air and self-reported release of lead in the air by industries (Alliance for
Healthy Homes and Environmental Defense, 2005; U.S. Environmental Protection Agency,
2010). Soil lead contaminations are also another means of lead exposure. One study suggested
that, in addition to industry, soil lead contamination may be attributed to historically high
traffic flow in communities due to the use of tetraethyl lead in gasoline from the 1920’s until
1986 (Mielke, Powell, Gonzales, & Mielke Jr, 2007).
Another significant lead exposure source is in the household. These include housing
units built prior to 1950 and low-income households. A study conducted on household lead in
U.S. homes found that lead dust on the floor and windowsills was significantly increased in pre1950’s homes, areas where people smoked, and pre-1950’s homes with chipping paint
(Gaitens, et al., 2009). The same study also found that homes of non-Hispanic black individuals
in the United States had significantly higher levels of lead dust than any other ethnic group
(Gaitens, et al., 2009). Carpeted floors also posed a higher risk of exposure to lead as lead dust
was more difficult to clean from a carpeted floor (Yiin, Lioy, & Rhoads, 2003).
The many means of exposure to lead create high variability in BLLs in the United States
population and also make it difficult to identify a primary source to target for intervention.
Some studies have been able to identify the lead sources in specific regions and have tested
interventions to reduce the amount of lead in the environment. In one study, for example,
childcare and community center playgrounds with top soil contaminated by lead in New
3

Orleans, Louisiana were covered with geotextile followed by a layer of river alluvium (Mielke, et
al., 2010). The intervention succeeded in significantly reducing the soil lead levels, but did not
eliminate the threat of chronic low level lead exposure since very low traces of lead could still
be detected. Environmental interventions have demonstrated the need for a thorough
understanding of molecular mechanisms activated by lead exposure in order to develop
primary preventive methods that can be applied to children at risk of exposure.
Overview of the Effect of Lead on Health and Wellbeing
Lead is able to enter mammalian systems through direct contact, ingestion, or inhalation
(Agency for Toxic Substances and Disease Registry, 2010). A percentage of the lead that enters
the body is absorbed, while the remainder is excreted in urine, nails, hair and sweat (Centers
for Disease Control and Prevention, 2005). Once lead is absorbed into the body, it is
transported to the liver, renal cortex, aorta, brain, lungs, spleen, teeth, and bones via
erythrocytes (Patrick, 2006; Sun, Ma, Chao, Liu, & Yuan, 2009).
Lead has been found to cause a number of adverse health outcomes that affect the
nervous system, reproductive system, kidneys, blood and endocrine systems at BLLs above 10
μg/dL (Sanborn, Abelsohn, Campbell, & Weir, 2002). Children are more susceptible to the
damaging effects of lead as their bodies absorb approximately 50 percent of the lead they
intake (adults only absorb 10 percent) and because of the increased hand to mouth activity in
children (Centers for Disease Control and Prevention, 2007). Clinical symptoms associated with
lead toxicity include hypertension, decreased nerve conduction velocity, tremors, increased
intracranial pressure, and abdominal pain amongst other symptoms (Vaziri, Ding, & Ni, 2001;
Agency for Toxic Substances and Disease Registry, 2007). High body lead levels can also cause
4

anemia, severe central nervous system effects and even death (Agency for Toxic Substances
and Disease Registry, 2007).
It is widely known and accepted that acute lead exposures are dangerous and can be
deadly (Centers for Disease Control and Prevention, 2007), but chronic exposure to low level
lead in children may be of equal or greater concern. Low-level lead is thought to be
detrimental to health despite the absence of diagnosable signs of toxicity. A number of clinical
studies have suggested that low BLL negatively affect intellectual and academic performance,
IQ, postural balance, reaction time, visual-motor integration, and fine motor skills in children
(Bellinger, Stiles, & Needleman, 1992; Canfield, et al., 2003; Lanphear, et al., 2005; Lanphear,
Dietrich, Auinger, & Cox, 2000; Nevin, 2009; Bhattacharya, Shukla, Dietrich, & Bornschein, 2006;
Chiodo, Jacobson, & Jacobson, 2004; Despres, et al., 2005; Kordas, et al., 2006). In addition, a
mean BLL of 0.73 μg/dL (maximum 2.2 μg/dL) in a study group was found to be correlated with
attention-deficit/hyperactivity disorder (Nigg, Nikolas, Knottnerus, Cavanagh, & Friderici, 2010).
Changes in cognition, motor ability, and behavior in children imply that lead is affecting the
central nervous system at the molecular level at BLLs below the current threshold of action
(Canfield, et al., 2003; Cecil, et al., 2008).
Recent studies of low-income minority children have shown that more than fifty percent
had BLLs between 2.5 and 5.0 μg/dL (Sobin et al., 2009, Sobin et al., 2011) suggesting that the
problem may affect millions of children nationwide. Similar to past studies, recent studies have
also shown that these same low BLLs are associated with specific deficits in working memory
and motor dexterity (Sobin, 2014). The brain mechanisms that account for these effects are not
currently known.
5

Knowledge of the molecular mechanisms underlying brain changes following early
chronic low-level lead exposure is essential for understanding findings from child behavioral
studies, and is also critical for developing primary preventive measures to reduce effects in
exposed children. It is important to note that in this report, “low-level” refers to chronic lead
exposure resulting in BLLs below the current CDC “reference level” of 5 μg/dL.
Molecular Mechanisms of Lead Toxicity
Little is known regarding the molecular mechanisms that account for central nervous
system effects during and following early chronic low-level lead exposure. A possible
mechanism of lead toxicity in organ systems outside of the central nervous system is the
accumulation of δ-aminolevulinic acid (δ-ALA) (Ahamed & Siddiqui, 2007). The accumulation of
δ-ALA occurs in blood and urine as lead inhibits δ-aminolevulinic acid dehydratase function
during heme synthesis in the mitochondrion (Ahamed & Siddiqui, 2007; Wang, Wu, & Zhang,
2005). The accumulation of δ-ALA was believed to cause oxidative stress when the unused δALA molecules are oxidized to a number of reactive oxygen species (Hermes-Lima, 1995).
The brain is an extremely sensitive organ, which uses the blood brain barrier to control
the flow of nutrients and molecules in and out of the brain, which enables the body to maintain
an environment that promotes normal brain function and development (McCance & Huether,
2010). It was believed that excess δ-ALA due to lead exposure bypassed the blood brain barrier
and increased oxidative stress in the brain, however a study conducted on adult rats found that
excess δ-ALA in plasma had low blood brain barrier permeability and a mechanism in the
choroid plexus released excess δ-ALA in cerebrospinal fluid into the peripheral blood supply
which may protect the brain from excess δ-ALA in plasma (Ennis, et al., 2003).
6

While it is unknown how lead enters the brain or how lead causes alterations in normal
brain function, it is known that lead is a heavy metal with no known nutritional value and has
chemical properties similar to other metals, which are essential to normal biological function
such as calcium, zinc, and iron (Flora, Gupta, & Tiwari, 2012). Lead’s chemical properties may
allow the metal to use transport mechanisms that the essential metals use to enter the brain to
bypass the blood brain barrier and directly interfere with mechanisms taking place in the brain.
A study found that lead molecules are present in brain tissue of mice exposed to 0.1 mL
or 0.2 mL of lead nitrate solution via vein injection (Sun, Ma, Chao, Liu, & Yuan, 2009). Studies
of C57BL/6J mice reported specific morphological changes in microglia and loss of dentate
gyrus volume in mice exposed to 40 ppm and 230 ppm lead acetate via the dam’s milk from
birth until weaning (Sobin, et al., 2013). Astrocytes appear to react to lead exposure at higher
rates than neurons, which are mostly non-responsive, but, both types of cells are believed to be
harmed (Cabell, et al., 2004; Qian, Zheng, Ramos, & Tiffany-Castiglioni, 2005b). The
morphological changes in microglia and neural cells suggest that a neuroinflammatory response
may be elicited by low-level lead which may explain the behavioral and motor dysfunctions
observed in children. Neuroinflammation exacerbates neurodegenerative disorders such as
Alzheimer’s Disease (Rosenberg, 2005) and Parkinson’s Disease (Hirsch & Hunot, 2009; KastenJolly & Lawrence, 2011). Alzheimer’s Disease and Parkinson’s Disease are severe examples of
neurodegenerative disorders triggered by neuroinflammation.
The neuroinflammatory response is believed to be generated by activated endothelium
and microglia, which secrete a number of bioactive molecules in response to alterations in the
brain’s environment (Anthony & Campbell, 2002). The molecules secreted include pro7

inflammatory cytokines, which trigger the cascade of mechanisms making an inflammatory
response, and anti-inflammatory cytokines that counter the effects of pro-inflammatory
cytokines (Conti, et al., 2008). Unlike the inflammatory response in other parts of the body,
anti-inflammatory cytokines are released simultaneously with pro-inflammatory cytokines to
minimize damage to the brain (Strle, et al., 2001). It is also important to note that while these
molecules play significant roles in immune and inflammatory responses in the brain, they have
also been found to participate in reconstruction of neurons and programmed cell death during
normal development (Sanes, Reh, & Harris, 2012).
It is possible that lead alters the normal function, release, and activation of a number of
cytokines and biological markers of oxidative stress in the brain. The current study observed
the effects of lead on the mRNA levels of Tumor Necrosis Factor α (TNF-α), Interleukin 6 (IL-6),
Interferon γ (IFN-γ), Heme oxygenase 1 (Hmox-1), inducible Nitric Oxide Synthase (iNOS),
Interleukin 10 (IL-10) and Glucose-regulated Protein of 78 kDa (GRP-78) (Ahamed & Siddiqui,
2007; Bokara, et al., 2008; Cabell, et al., 2004; Garcia-Arenas, Claudio, Perez-Severiano, & Rios,
1999; Gastaldello Moreira, de Magalhaes Rosa, Moraes Barros, Vassilieff, & Vassillieff, 2001;
Jones, et al., 2008; Qian, Zheng, Weber, & Tiffany-Castiglioni, 2007; Strle, et al., 2001). These
markers fall under three broad categories: pro-inflammatory cytokines (TNF-α, IL-6, iNOS and
IFN-γ), anti-inflammatory cytokines (IL-10, Hmox-1), and a chaperone (GRP-78). The markers
observed in the current studies were selected because they have been found to have roles in
brain development and inflammatory response (Bauer, Kerr, & Patterson, 2007; Ahamed &
Siddiqui, 2007; Anthony & Campbell, 2002; Bokara, et al., 2008; Cabell, et al., 2004; Deverman
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& Patterson, 2009; Gastaldello Moreira, de Magalhaes Rosa, Moraes Barros, Vassilieff, &
Vassillieff, 2001).
TNF-α is a key inflammatory cytokine that has been extensively studied for its role in the
immune response. The TNF cytokine family is known to participate in developmental neuronal
cell death (Sanes, Reh, & Harris, 2012). A study of mouse pups exposed to 0.1%, 0.5%, and 1%
lead acetate in distilled water found that the presence of TNF-α increased with increasing lead
exposure in the hippocampus (Li, et al., 2009).
Another inflammatory cytokine, IL-6, induces acute phase proteins during the
inflammatory response (McCance & Huether, 2010). Aside from being known as an
inflammatory cytokine, IL-6 is also categorized as a neuropoietic cytokine and is believed to
have a role in regulation of neurogenesis (Erta, Quintana, & Hidalgo, 2012; Bauer, Kerr, &
Patterson, 2007). The results of a study conducted to determine the effects of IL-6 on the brain
suggested that the cytokine reduced behavioral dysfunction by suppressing microglial
activation and increasing the number of oligodendrocytes in rats exposed to lipopolysaccharide
(Pang, L.W, Zheng, Cai, & Rhodes, 2006). IL-6 is believed to have neuroprotective effects and
reduced expressions of the cytokine during insult have been associated with increased
oxidative stress and higher damage to neurons (Penkowa & Hidalgo, 2000). Lead exposure may
reduce the expression of this cytokine and thus also reduce protective properties this cytokine
activates in human glioma cells (Liu, Hsieh, & Yang, 2000).
It is possible that IFN-γ is released by microglia and blood-derived macrophages in the
brain (Suzuki, Claflin, Wang, Lengi, & Kikuchi, 2005). The effect of IFN-γ has been studied on
cultures of mouse cortical neurons. Findings from a study indicate that IFN-γ reduced
9

intracellular ATP levels and caused formation of dendritic beads and neuron damage in vitro
(Mizuno, et al., 2008). Little is known about the effect of lead on IFN-γ expression in the brain,
however studies have found neuritic beading which suggests the activation of IFN- γ (Jones, et
al., 2008).
INOS is activated to induce nitric oxide generation during neuro immune responses
(Zielinska, et al., 2015). iNOS generates nitric oxide by catalyzing a reaction which converts Larginine to L-citrullinei. Nitric oxide is a byproduct of the reaction. Increased levels of nitric
oxide have been found to be associated with neuronal loss. Garcia-Arenas and colleagues
(1999) have reported that lead may increase the expression of iNOS and thus, increase the
production of nitric oxide. The subsequent increase of iNOS may lead to higher oxidative stress
and cause damage to brain function.
On the other hand, anti-inflammatory cytokines are also produced during the
inflammatory process to counteract the potentially damaging effects caused by proinflammatory cytokines and oxidative stress. The anti-inflammatory cytokine, IL-10, is
important in reducing synthesis of pro-inflammatory cytokines and inhibiting the expression
and activation of cytokine receptors (Strle, et al., 2001). The expression of this cytokine was
observed to determine whether anti-inflammatory mechanisms were being activated to reduce
the harms of pro-inflammatory cytokines induced by low-level lead exposure (Strle, et al.,
2001). The control of pro-inflammatory cytokine production is necessary to reduce the
potentially damaging effects of these cytokines to the brain.
Hmox-1 was found to inhibit pro-inflammatory responses and maintain expression of IL10 induced by lipopolysaccharide exposure (Chauveau, et al., 2005). The Hmox-1 antioxidant
10

enzyme is activated in response to oxidative stress and breaks down heme groups into
biliverdin, iron(II), and carbon monoxide (Schipper, 2000; Ryter & Tyrrell, 2000). Biliverdin
metabolizes into bilirubin which serves as an antioxidant (Ryter & Tyrrell, 2000). Oxidative
stress has been found to increase the presence of Hmox-1 during exposure to organic lead in
cultured hippocampal astrocytes (Cabell, et al., 2004).
Finally, the 78-kDa glucose-regulated protein (GRP-78) is believed to be important in
regulating mechanisms that reduce oxidative stress (Qian, Zheng, Ramos, & Tiffany-Castiglioni,
2005a; Qian, Zheng, Ramos, & Tiffany-Castiglioni, 2005b; Qian, Zheng, Weber, & TiffanyCastiglioni, 2007; White, et al., 2007). Studies have shown that lead may increase oxidative
stress indirectly by binding to GRP-78 (Qian, Zheng, Ramos, & Tiffany-Castiglioni, 2005a). Once
lead binds to GRP-78, the protein protects neurons by removing lead molecules, but by doing
so, it loses its ability to activate anti-oxidant mechanisms (Qian, Zheng, Ramos, & TiffanyCastiglioni, 2005a). GRP-78 is known to increase the expression of IL-6 during normal
circumstances and is also thought to have an indirect role in the generation of reactive oxygen
species (Qian, Zheng, Ramos, & Tiffany-Castiglioni, 2005a). Once lead molecules bind GRP-78,
the chaperone accumulates and increases reactive oxygen species generation, but cannot
activate release of IL-6 (Qian, Zheng, Weber, & Tiffany-Castiglioni, 2007).
Study Rationale
The studies here described were part of a larger program of translational
interdisciplinary research examining the effects on brain and behavior of early chronic low-level
lead exposure (Flores-Montoya & Sobin, 2015; Flores-Montoya, Alvarez, & Sobin, 2015; Sobin,
Flores-Montoya, Gutierrez, Parisi, & Schaub, 2015; Sobin, et al., 2013; Sobin, Parisi, Schaub,
11

Gutierrez, & Ortega, 2011; Sobin, Gutierrez, & Alterio, 2009). An understanding of molecular
mechanisms activated by chronic low-level lead exposure is needed to understand the results
of child behavioral studies and to provide the data needed to assist in adjusting policies that set
guidelines for the use and handling of lead. Understanding inflammatory immune response in
the brain is also necessary to develop primary preventive measures that can ameliorate
exposure to low lead levels. The majority of studies conducted to date on neuroinflammatory
responses to lead have examined effects of lead exposures that would produce BLLs higher
than the current CDC “threshold of concern” of 5 μg/dL and studies at lowest level exposures
are needed. Currently, no preventive measures exist for the effects of chronic low-level lead.
Medical treatment is available only for severe acute cases (Patrick, 2006). The findings of this
study may be useful in guiding further studies that attempt to develop preventive measures
targeting neuroinflammation.
In many prior studies of neuroimmune response following lead exposure in vitro
methods were used (Garden & Moller, 2006). In vitro studies alone may provide only a partial
understanding of neuroinflammatory responses. These studies examined isolated cells such as
microglia and astrocytes and could not suggest possible synergistic mechanisms involving other
cytokines (Harry & Kraft, 2008).
In the studies here described, cytokine gene expression was examined in two studies of
brain tissue from pre-adolescent and adult mice exposed to low and higher levels of lead as
compared with controls. Total cytokine gene expression, and the balance of cytokine gene
expression in defined brain regions, were examined. As discussed above, there were a number
of possible markers of mechanisms related to inflammatory responses secondary to lead12

induced neurotoxicity (Harry & Kraft, 2008). The inflammatory markers measured in the study
were selected because of their major roles in pro-inflammatory and anti-inflammatory
responses. Study 1 (pre-adolescent mice) examined pro-inflammatory IL-6, TNF-α, IFN-γ, and
iNOS, the GRP78 chaperone, and the anti-inflammatory markers IL-10 and Hmox-1 in anterior
and posterior brain regions. Study 2 (young adult mice) examined the same markers in
anterior, posterior and cerebellar regions.
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CHAPTER II: STUDY AIMS AND HYPOTHESIS
Specific Aims
Aim 1: To determine whether chronic lead exposure alters the levels of cytokine gene
expression and/or oxidative stress marker gene expression in mouse brain at
pre-adolescence and/or at early adulthood.
Aim 2: To determine whether chronic lead exposure alters the balance of cytokine
gene expression and/or oxidative stress marker gene expression in mouse brain
at pre-adolescence and/or early adulthood.
Hypotheses
It was hypothesized that chronic exposure to low-level lead contributes to brain disruption
through its effect on the balance of the expression of pro-inflammatory and anti-inflammatory
markers. Specifically, lead would cause a dose-dependent reduction of IL-6 through the
inhibition of GRP-78. Pro-inflammatory cytokines (TNF-α, IFN-γ, and iNOS) would also be
expressed at higher than normal concentrations as the brain responds to lead exposure. In
response to the increase in oxidative stress and pro-inflammatory cytokine expression, antioxidant (Hmox-1) and anti-inflammatory (IL-10) marker expression would also increase to
reduce the harm of oxidative stress and inflammatory mechanisms. The posterior cerebrum
would be most susceptible to abnormal genetic expression of markers due to lead exposure.
Since previous studies had not compared different effects in pre-adolescent and young adult
mice, no hypotheses were proposed for possible age effects.
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CHAPTER III: METHODS AND MATERIALS
Ethical Treatment of Animals
The experimental animal study was approved by the University of Texas at El Paso
Institutional Animal Use Committee (Protocol #A-200804, C. Sobin, PI)
Experimental Protocol
Two experimental studies were conducted using a total of forty C57BL/6J mice (Jackson
Laboratories, Sacramento, CA). In Study 1, brain tissue from 16 C57BL/6J mice (10 males/6
females) was harvested. The mice in Study 1 were sacrificed at 28 days of age, the age just
preceding the onset of adolescence. In Study 2, brain tissue from 24 C57BL/6J mice (17 males/7
females) was harvested. The mice in Study 2 were sacrificed at 40 days of age, the age when
mice reach sexual maturity. Both studies included two experimental groups and one control
group. The experimental mice were exposed to lead through the milk of the dams. The dams
were exposed to lead through the addition of lead acetate to their drinking water. The
exposures to lead lasted from birth until weaning (post-natal day 21). The experimental groups
consisted of a group exposed to 40 ppm lead acetate (low dose group) and a group exposed to
230 ppm lead acetate (high dose group). The third group served as the control and was not
exposed to any lead acetate. The mice lived in a 12 hour light to 12 hour dark day cycle. All
mice lived in cages equipped with a paper/plastic hut, bedding, and nestlet enrichment.
After 28 (Study 1) or 40 days (Study 2), the mice were sacrificed to conduct
immunological studies on brain tissues. The brain tissue was harvested within one minute of
sacrifice and was fresh frozen on dry ice. All brain tissue was stored at -80⁰C until RNA
extraction. Blood samples obtained from the heart and randomly selected brains from each
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group were sent to the New Mexico State University in Las Cruces, New Mexico to obtain blood
and brain lead levels of mice in the study using Inductively Coupled Plasma Mass Spectrometry.
RNA Extraction from Fresh Frozen Brain
RNA was extracted using Ambion’s RiboPureTM Kit (Life Technologies, 2006). Each fresh
frozen brain was cut into three segments: the anterior cerebrum, the posterior cerebrum, and
the cerebellum. After the cerebellum was removed, the anterior and posterior portions were
divided into two equal portions. The samples were sliced within one minute and were quickly
transferred to glass homogenizers where the tissue was homogenized for less than thirty
seconds to break down large tissues. TRI Reagent was immediately added after initial
homogenization.
The anterior cerebrum included the following brain structures: basal forebrain, striatum,
ventral striatum and septum. The posterior cerebrum included the midbrain, hippocampus,
amygdala, thalamus, and hypothalamus. The medulla and pons were analyzed with the
cerebellum.
The following procedures were followed as stated in the RiboPureTM Kit protocol and
were included to describe specific amounts of reagents added as they were adjusted to the size
of brain tissue used. Each of the three brain segments were homogenized with 400 μL of TRI
Reagent® individually. After the brain segment was homogenized, 100 μL of chloroform
(without isoamyl alcohol) was added to the homogenate and vortexed for 15 seconds. The
mixture was then allowed to incubate for five minutes at room temperature.
After incubation, the mixture was centrifuged at 12,000 x g at room temperature for ten
minutes. The mixture separated into three phases (as described in the protocol): an organic
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phase, an interphase, and an aqueous phase. The top aqueous phase layer was transferred to a
new 1.5 microcentrifuge tube. Once in a new tube, 100 μL of 100% ethanol was added to the
aqueous phase and vortexed immediately for five seconds. The sample was then transferred to
a filter cartridge and collection tube supplied in the kit.
The filter and collection tube was centrifuged at 12,000 x g for 1 minute at room
temperature to pass all the liquid through the filter and ultimately bind the RNA to the filter.
The flow-through liquid was discarded and then the filter replaced in the collection tube. An
aliquot of 250 μL of Wash Solution was be added and the tube was again centrifuged at 12,000
x g for 1 minute. The flow through was discarded and a second wash was conducted with
another 250 μL of Wash Solution. Once again, the tube was centrifuged at 12,000 x g for 1
minute and the filter was placed in a new collection tube. Once the filter was in a new tube, 40
μL of Elution Buffer was added to recover the RNA from the filter. Once the Elution Buffer was
added, the tube was incubated for 2 minutes. After incubation, the tube was centrifuged at
12,000 x g for 90 seconds.
Due to the possibility of DNA presence in the extracted RNA, DNase obtained from
Invitrogen was added to digest any remaining DNA. To each RNA sample, one μL of 10X DNase I
Reaction Buffer and one μL of DNase I Amplification grade was added. The RNA and DNase
mixture was then incubated at room temperature for 15 minutes. At the end of the incubation
period, one μL of 25 mM EDTA solution was added and the mixture was heated to 65oC for ten
minutes to inactivate the DNase. After treatment with DNase, RNA concentration was obtained
using the ND-1000 machine from NanoDrop Technologies.
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cDNA Synthesis
The synthesis of cDNA was conducted immediately after RNA extraction to reduce
possible RNA degradation. The cDNA was synthesized using the High Capacity cDNA Reverse
Transcription Kit from Applied Biosystems.
A master mix was created containing all the items in Table 2 according to the number of
reactions that were conducted. Ten μL of the prepared master mix was combined with ten μL
of extracted RNA in a 0.2 mL tube. The tubes were then centrifuged briefly to collect contents
at the bottom of the tubes and were then loaded into a GeneAmp® PCR System 9700 thermal
cycler manufactured by Applied Biosystems. The thermal cycler followed the cycling program
described in Table 3. After the program was completed, the tubes containing cDNA were
stored at -80oC until they were used for gene expression analysis.
Gene Expression Analysis
Gene expression analysis was used to quantify inflammatory markers using Quantitative
Real Time Polymerase Chain Reaction (qRT-PCR) techniques. TaqMan® probes were ordered
from Applied Biosystems for each of the biomarkers analyzed and β-actin served as the
reference gene. Table 4 describes each biomarker and its corresponding primers. A 96-well
qRT-PCR plate was prepared with each well containing an amount of cDNA equivalent to 500 ng
of RNA, 1 μL TaqMan® probe, 10 μL TaqMan® Universal Master Mix, and an amount of
nuclease-free water that brought the total volume in the well to 20 μL. Once the plate was
filled with the samples to be analyzed, it was placed in an iCycler iQTM Optical Module thermal
cycler manufactured by BIO RAD. The cycling program that the thermal cycler followed is

18

described in Table 5. Data was collected during Step 2 of Cycle 3. Duplicate wells of all samples
were run to ensure that reading was consistent for each sample.
Data and Statistical Analysis
qRT-PCR data was analyzed by Relative Quantification using a reference gene (β-actin).
The analysis was completed by using the ΔCT Method using a reference gene (Kasten-Jolly, Heo,
& Lawerence, 2011; Bio-Rad Laboratories, Inc., 2005), which produces normalized expression of
target genes relative to the reference gene (β-actin). The following equation was used to
obtain normalized expression of target genes:
𝐶𝐶𝑇𝑇 = 𝑇𝑇ℎ𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

∆𝐶𝐶𝑇𝑇 = 2𝐶𝐶𝑇𝑇 𝛽𝛽−𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 − 𝐶𝐶𝑇𝑇 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 × 1000

IBM SPSS Statistics 22.0 software was used for all analyses. Possible group differences
in the balance of cytokine gene expression in different brain regions were tested using a 3 x 2 (3
lead exposure groups by 2 brain regions tested), or a 3 x 3 (3 lead exposure groups by 3 brain
regions tested) two-way mixed method ANOVA. Type III sum of squares were used to
determine statistically significant differences. Tukey’s Honest Significant Difference was
conducted on significant ANOVA results.
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CHAPTER IV: RESULTS
Study 1: Pre-adolescent Mice
qRT-PCR analyses were conducted on the anterior cerebrum, posterior cerebrum, and
cerebellum of pre-adolescent mice (N = 16). Analysis of data obtained from cerebellar tissue
could not be conducted due to low yields of RNA obtained from the harvested tissue. The low
RNA yields did not produce accurate readings by the iCycler iQTM Optical Module thermal
cycler. Table 5 displays the mean genetic expression and standard deviation of each targeted
biomarker relative to the reference gene, β-actin. The following results of the 3x2 (3 exposure
groups x 2 brain regions) two-way mixed method ANOVA conducted for Study 1 were obtained
for each biomarker. The main effect of brain region (not considering lead exposure) was
analyzed to determine if any significant difference in expression of markers was observed
between brain regions. Then statistical analysis was conducted taking brain region and lead
exposure group into consideration. Any significant difference was further analyzed by Tukey
post hoc tests.
TNF-α
A total of 14 brain samples were analyzed (nCONTROL = 6, nLOW DOSE = 4, and nHIGH DOSE = 4).
There was a significant main effect of brain region tested in the expression of TNF-α (F1, 11 =
18.7, p = 0.001; ηp2 = 0.63). There was no significant difference in genetic expression of TNF-α
when considering both, brain region and lead exposure group (F2, 11 = 0.17, p = 0.85).
IL-6
A total of 14 brain samples were analyzed (nCONTROL = 6, nLOW DOSE = 4, and nHIGH DOSE = 4).
There was a significant main effect of brain region tested in the expression of IL-6 (F1, 11 = 34.9, p
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< 0.001; ηp2 = 0.76). There was no significant difference in genetic expression of IL-6 when
considering both, brain region and lead exposure group (F2, 11 = 3.37, p = 0.072), however the
Type III SS for the exposure group effect was significant (F2, 11 = 8.87, p = 0.005; ηp2 = 0.62).
IFN-γ
A total of 12 brain samples were analyzed (nCONTROL = 6, nLOW DOSE = 4, and nHIGH DOSE = 2).
There was no significant main effect of brain region tested in the expression of IFN-γ (F1, 9 =
0.45, p = 0.84). There was no significant difference in genetic expression of IFN-γ when
considering both, brain region and lead exposure group (F2, 9 = 1.15, p = 0.36).
Hmox-1
A total of 12 brain samples were analyzed (nCONTROL = 5, nLOW DOSE = 3, and nHIGH DOSE = 4).
There was no significant main effect of brain region tested in the expression of Hmox-1 (F1, 9 =
1.49, p = 0.25). There was no significant difference in genetic expression of Hmox-1 when
considering both, brain region and lead exposure group (F2, 9 = 0.61, p = 0.56).
iNOS
A total of 13 brain samples were analyzed (nCONTROL = 6, nLOW DOSE = 4, and nHIGH DOSE = 3).
There was no significant main effect of brain region tested in the expression of iNOS (F1, 10 =
4.93, p = 0.051). A significant difference in genetic expression of iNOS was observed when
considering both, brain region and lead exposure group (F2, 10 = 10.26, p = 0.004; ηp2 = 0.67),
however Type III SS for the exposure group effect was not significant (F = 0.76, p = 0.49).
Tukey’s post hoc analyses also showed no significant difference between any of the exposure
groups.
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IL-10
A total of 13 brain samples were analyzed (nCONTROL = 6, nLOW DOSE = 4, and nHIGH DOSE = 3).
There was a significant main effect of brain region tested in the expression of iNOS (F1, 10 = 5.68,
p = 0.038; ηp2 = 0.36). A significant difference in genetic expression of IL-10 was observed when
considering both, brain region and lead exposure group (F2, 10 = 6.74, p = 0.014, ηp2 = 0.57),
however Type III SS for the exposure group effect was not significant (F2, 10 = 0.14, p = 0.88).
Tukey’s post hoc analyses also showed no significant difference between any of the exposure
groups.
GRP-78
A total of 15 brain samples were analyzed (nCONTROL = 6, nLOW DOSE = 5, and nHIGH DOSE = 4).
There was a significant main effect of brain region tested in the expression of GRP-78 (F1, 12 =
6.34, p = 0.027; ηp2 = 0.35). There was no significant difference in the genetic expression of
GRP-78 when considering both, brain region and lead exposure group (F2, 12 = 0.36, p = 0.71).
Study 2: Young Adult Mice
qRT-PCR analyses were conducted on anterior cerebrum, posterior cerebrum, and cerebellum
of young adult mice (N = 21). Table 6 displays the mean genetic expression and standard
deviation of each targeted biomarker relative to the reference gene, β-actin. Due to low RNA
yields of some cerebellar tissues, the expression of iNOS, IL-10, and GRP-78 was not collected
on some of the test samples. A 3x3 two-way mixed method ANOVA was conducted for TNF-α,
IL-6, IFN-γ, and Hmox-1. A 3x2 two-way mixed method ANOVA was chosen to analyze group
differences in genetic expression of iNOS, IL-10 and GRP-78 because a 3x3 two-way mixed
method ANOVA would have reduced the sample size to one sample in some situations due to
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the absence of data on some test samples as explained above. The main effect of brain region
(not considering lead exposure) was analyzed to determine if any significant difference in
expression of markers was observed between brain regions. Then statistical analysis was
conducted taking brain region and lead exposure group into consideration. Any significant
difference was further analyzed by Tukey post hoc tests.
TNF-α
A total of 12 brain samples were analyzed (nCONTROL = 3, nLOW DOSE = 3, and nHIGH DOSE = 6).
There was no significant main effect of brain region tested in the expression of TNF-α (F2, 18 =
0.44, p = 0.71). A significant difference in the genetic expression of TNF-α was observed when
considering both, brain region and lead exposure group (F4, 18 = 3.08, p = 0.043; ηp2 = 0.41). The
Type III SS for the exposure group effect was also significant (F2, 9 = 8.15, p = 0.010; ηp2 = 0.64).
Tukey’s post hoc analyses showed a significant difference (p < 0.05) between the control group
and the low dose group; and also between the low dose group and the high dose group (Figure
1).
IL-6
A total of 15 brain samples were analyzed (nCONTROL = 4, nLOW DOSE = 4, and nHIGH DOSE = 7).
There was a significant main effect of brain region tested in the expression of IL-6 (F2, 24 = 11.70,
p < 0.001; ηp2 = 0.49). There was no significant difference in the genetic expression of IL-6
when considering both, brain region and lead exposure group (F4, 24 = 0.39, p = 0.81). The Type
III SS for the exposure group effect was significant (F2, 12 = 8.08, p = 0.006; ηp2 = 0.57)
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IFN-γ
A total of 15 brain samples were analyzed (nCONTROL = 4, nLOW DOSE = 4, and nHIGH DOSE = 7).
There was a significant main effect of brain region tested in the expression of IFN-γ (F2, 24 = 19.0,
p < 0.001; ηp2 = 0.75). There was no significant difference in the genetic expression of IFN-γ
when considering both, brain region and lead exposure group (F4, 24 = 1.69, p = 0.19), however
Type III SS for the exposure group effect was significant (F2, 12 = 9.38, p = 0.004; ηp2 = 0.61).
Hmox-1
A total of 14 brain samples were analyzed (nCONTROL = 3, nLOW DOSE = 4, and nHIGH DOSE = 7).
There was a significant main effect of lead exposure in the expression of Hmox-1 (F2, 11 = 10.4, p
= 0.003). There was a significant main effect of brain region tested in the expression of Hmox-1
(F2, 22 = 6.70, p = 0.005; ηp2 = 0.38). There was also a significant difference in the genetic
expression of Hmox-1 when considering both, brain region and lead exposure group (F4, 22 =
6.86, p = 0.001; ηp2 = 0.56). The Type III SS for the exposure group effect was also significant (F2,
11 =

10.4, p = 0.003; ηp2 = 0.65). Tukey HSD post hoc analyses showed a significant difference (p

< 0.01) between the control and low dose groups; and also between the low dose and high
dose groups (Figure 2).
iNOS (cerebellum not analyzed)
A total of 16 brain samples were analyzed (nCONTROL = 6, nLOW DOSE = 4, and nHIGH DOSE = 6).
There was a significant main effect of brain region tested on the expression of iNOS (F1, 13 =
8.36, p = 0.013; ηp2 = 0.39). There was no significant difference in the genetic expression of
iNOS when considering both, brain region and lead exposure group (F2, 13 = 1.43, p = 0.27).
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IL-10 (cerebellum not analyzed)
A total of 10 brain samples were analyzed (nCONTROL = 3, nLOW DOSE = 3, and nHIGH DOSE = 4).
There was no significant main effect of brain region tested on the expression of IL-10 (F1, 7 =
3.14, p = 0.12). There was no significant difference in the genetic expression of IL-10 when
considering both, brain region and lead exposure group (F2, 7 = 0.35, p = 0.72), however the
Type III SS for the exposure group effect was significant (F2, 7 = 7.15, p = 0.02; ηp2 = 0.67).
GRP-78 (cerebellum not analyzed)
A total of 16 brain samples were analyzed (nCONTROL = 6, nLOW DOSE = 4, and nHIGH DOSE = 6).
There was a significant main effect of brain region tested on the expression of GRP-78 (F1, 11 =
56.4, p < 0.001; ηp2 = 0.84). There was a significant difference in the genetic expression of GRP78 when considering both, brain region and lead exposure group (F2, 11 = 4.60, p = 0.035; ηp2 =
0.46). The Type III SS for the exposure group effect was also significant (F2, 11 = 7.15, p = 0.015;
ηp2 = 0.54). Tukey HDS post hoc analyses determined that there was a significant difference (p
< 0.05) between the low dose and high dose groups (Figure 3).
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CHAPTER V: DISCUSSION
Numerous studies have observed the effects of lead on specific inflammatory molecules
(Garcia-Arenas, Claudio, Perez-Severiano, & Rios, 1999; Li, et al., 2009; Qian, Zheng, Ramos, &
Tiffany-Castiglioni, 2005a; Qian, Zheng, Ramos, & Tiffany-Castiglioni, 2005b; Qian, Zheng,
Weber, & Tiffany-Castiglioni, 2007), but few have observed the expression of multiple markers
of innate immunity in brains of mice exposed to low levels of lead (Kasten-Jolly, Heo, &
Lawerence, 2011; Sobin, et al., 2013). In order to better understand the inflammatory response
elicited by chronic low level lead exposure, the current studies analyzed the expression of
multiple markers of inflammation that fell under one of four categories to determine how
exposures to chronic low levels of lead affected the expression of those markers and whether
balance of those markers in the brain was also affected. Expression of pro-inflammatory
cytokines (TNF-α, IL-6, and IFN-γ), oxidant regulating enzymes (Hmox-1 and iNOS), an antiinflammatory cytokine (IL-10), and a chaperone (GRP-78) were observed in brains of preadolescent and young adult C57BL/6J mice.
The studies aimed to determine whether chronic lead exposure altered the levels of
inflammatory cytokine gene expression and/or oxidative stress marker gene expression in
mouse brain at pre-adolescence and/or at early adulthood. The second aim was to determine
whether chronic lead exposure alters the balance of inflammatory cytokine gene expression
and/or oxidative stress marker gene expression in mouse brain at pre-adolescence and/or early
adulthood. Cytokines are expressed at varying levels due to the numerous roles and functions
that they have in immune responses and neurogenesis (Khan, 2008; Deverman & Patterson,
2009). The pro-inflammatory molecules tested in this study (TNF-α, IFN-γ and IL-6) are usually
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expressed at higher concentrations during brain disease and can contribute to neural damage
through their prolonged activation (Wilms, et al., 2010; Mizuno, et al., 2008; Qian, Zheng,
Ramos, & Tiffany-Castiglioni, 2005a). In the brain, anti-inflammatory mechanisms are usually
activated at the same time as pro-inflammatory ones to prevent extensive damage from the
pro-inflammatory molecules (Strle, et al., 2002). It has been found that IL-10 induces the
release and expression of Hmox-1 to reduce oxidative stress (Lee & Chau, 2002). Prior studies
have found that expression of IL-6 had an inverse relation to expression of GRP78 during lead
exposure (Qian, Zheng, Weber, & Tiffany-Castiglioni, 2007; Liu, Hsieh, & Yang, 2000).
Study 2: Genetic Expression and Distribution of TNF-α, Hmox-1, and GRP78
In young adult mice, the genetic expression of TNF-α (Figure 1), Hmox-1 (Figure 2), and
GRP78 (Figure 3) showed statistically significant differences when both lead exposure group
and brain segment were analyzed.
The expression of TNF-α and Hmox-1 followed similar expression patterns in the
anterior and posterior cerebrum in young adult mice. The two markers were most highly
expressed in the low dose group. These patterns suggest that lead was distributed throughout
the anterior and posterior cerebrum in the days that followed the end of lead exposure in the
mice in this study. Lead exposure in young adult mice ended at post-natal day 21, the same
time as pre-adolescent mice.
In the anterior portion of the brain, expression of TNF-α and Hmox-1 was significantly
higher in the low dose group when compared to the control group. This interaction was
interesting because it did not follow the expected dose response pattern. Through some
currently unknown mechanism, it appears that chronic lowest level lead exposure elicits an
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extended and more highly expressed inflammatory response. Additional testing should be
conducted in lowest level lead exposed animal models to further investigate this finding. The
expression difference of TNF-α and Hmox-1 between the control and high dose group was not
significant.
GRP78 was expressed in a manner that was different from that of TNF-α and Hmox-1,
however the statistically significant differences of GRP78 were found between low dose and
high dose groups. There was no statistical significance between the control group and either of
the experimental groups.
Summary of Observed Inflammatory Response
As hypothesized, pro-inflammatory (TNF-α) and anti-inflammatory (Hmox-1)
mechanisms were activated simultaneously in Study 2, however no statistically significant
findings were made in Study 1. The findings in Study 2 support previous studies describing the
activation of both pro- and anti-inflammatory mechanisms during neuroimmune activation
(Deverman & Patterson, 2009; Harry & Kraft, 2008; Kasten-Jolly & Lawrence, 2011; Strle, et al.,
2001). The simultaneous activation of pro- and anti- inflammatory mechanisms allows for the
activation of pro-inflammatory mechanisms in response to lead exposure and the antiinflammatory response may ameliorate some of the deleterious effects of extended activation
of the pro-inflammatory processes.
The expression of neuroinflammatory markers suggests an activated immune response
that support findings of microglial disruption by previous studies (Sobin, et al., 2013). Cytokines
and inflammatory molecules have been found to have varying roles during neurogenesis.
Studies have found that chronic exposure to low-level lead alters mouse exploratory function,
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olfactory recognition, and aggression (Flores-Montoya & Sobin, 2015; Flores-Montoya, Alvarez,
& Sobin, 2015; Kasten-Jolly, Pabello, Bolivar, & Lawrence, 2012). It is unclear however, whether
these changes in behavior are a result of extended activation of neuroimmune processes
causing damage to the brain or if interference caused by low-level lead exposures prevent
normal brain development.
A study conducted by Giedd et al. found that cerebral volume peaks a 14.5 years in
human males and 11.5 years in human females. The study further found that by age 6, the
brain is at approximately 95% of that peak in both males and females (Lenroot & Giedd, 2006;
Giedd, et al., 1999). By interfering with normal expression and balance of neuroinflammatory
processes, lead may affect normal brain development during childhood, a vital time period for
that development. This may explain loss of gray matter in portions of the prefrontal cortex in
the brains of adults exposed to lead during childhood (Cecil, et al., 2008).
Strengths
The studies, presented, were among the first to observe the in vivo expression of
multiple pro-/anti-inflammatory markers in animal models exposed to chronic low levels of
lead. There are many different markers involved in brain development and neuroinflammatory
responses. The markers observed in the current studies were selected because they have been
found to have roles in brain development and inflammatory response (Bauer, Kerr, & Patterson,
2007; Ahamed & Siddiqui, 2007; Anthony & Campbell, 2002; Bokara, et al., 2008; Cabell, et al.,
2004; Deverman & Patterson, 2009; Gastaldello Moreira, de Magalhaes Rosa, Moraes Barros,
Vassilieff, & Vassillieff, 2001). Despite not being able to define specific mechanisms of
detrimental effects caused by chronic low level lead exposure in the brain, this study can be
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used to focus future research on the pathways associated with the expression of iNOS and IL-10
in pre-adolescent mice and TNF-α, Hmox-1 and GRP78 in young adult mice.
Another strength of the current study was that the measurement of inflammatory
marker expression was conducted for two age groups. This is significant because the observed
expression of some of the genetic markers showed that chronic exposure to lowest levels of
lead continue to affect neuroinflammatory responses after the exposure is halted.
The studies also measured genetic expression of inflammatory markers in three
different brain segments. Few studies have analyzed expression of inflammatory markers in
different brain regions after chronic low level lead exposure (Kasten-Jolly, Pabello, Bolivar, &
Lawrence, 2012; Sobin, et al., 2013; Kasten-Jolly, Heo, & Lawerence, 2011). Measurement of
the expression of the selected inflammatory markers in three different brain regions allowed
for the observation of what can potentially be different exposure and response patterns in the
anterior cerebrum, posterior cerebrum, and cerebellum of pre-adolescent and young adult
mice tested.
Finally, the study exposed test animals to concentrations of lead that typically result in
BLLs that fall below the current threshold of action as described by the CDC. The current study
showed that TNF-α and Hmox-1 were expressed more highly in young adult mice exposed to
the lowest levels of lead. These findings suggest that lowest level lead exposures may cause an
extended and more heightened neuroinflammatory response that can cause further damage or
obstruction to normal brain function.
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Limitations
A high variability in some of the results can be explained by the following factors: low
RNA yields, smaller than expected sample sizes, and varying lead levels within each exposure
group. RNA yields in some of the samples were too low despite homogenizing brain tissue
quickly in TRI Reagent. This led to smaller sample sizes than expected when analyzing gene
expression of some of the cytokines. The qRT-PCR equipment requires specific RNA
concentrations in order to accurately detect the signals elicited by the TaqMan® Probes. In
addition to RNA yields, some of the cytokines measured are expressed at minimal levels which
may create additional difficulties in qRT-PCR detection. Use of alternate kits for the extraction
of RNA from fatty tissues may increase the RNA yielded. It may also be beneficial that future
studies pool brain tissue from 2-3 brains within the same exposure group in order to reduce
error caused by low RNA yields. Lead levels in mice in the present studies were dependent on
the amount of water that the dam drank and on the amount of dam milk consumed by the pup.
This variability caused by this issue may be addressed by having larger sample sizes in each
exposure group.
Some studies have found that males and females are affected differently to lead
exposure. One study found that male mice exposed to low levels of lead had increased
“aggressive behavior toward a stranger,” while female mice demonstrated a lower exploratory
behavior (Kasten-Jolly, Pabello, Bolivar, & Lawrence, 2012). The use of natural litters in these
studies did not allow control for sex. Analysis of data by sex could not be conducted due to the
lower number of female mice available. Future studies can be designed to observe differences
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in expression of markers of inflammation in female and male mice exposed to chronic low
levels of lead.
Implications of Findings to Public Health
The findings of the study suggest that lowest level lead exposures may trigger
mechanisms throughout brain development that cause behavioral and motor dysfunctions in
children.
Studies such as this one provide information that can be used to determine how chronic
low level lead exposures may affect normal functioning of the brain and can have federal, state
and local policies recognize that low level lead may be harmful to children, even at BLLs below 5
μg/dL. Changes in policy can allow for additional funding for improved epidemiological data
collection and follow up. Currently, the CDC recommends that action and reporting be
conducted on cases with BLLs ≥ 5 μg/dL, although it does recognize that there is no known safe
threshold for lead (Centers for Disease Control and Prevention, 2014). The state of Texas, on

the other hand, requires that all positive blood lead tests in children younger than 15 years of
age be reported; regardless of whether the results are elevated or not (Texas Department of
State Health Services, 2014). The stricter policy sets a standard that improves surveillance of
BLLs in communities. The surveillance data, in turn, can be used to identify clusters of exposure
for further epidemiological investigation and implementation of non-pharmaceutical control
measures. Surveillance data can also be used to characterize the extent of lead availability
throughout the United States and identify specific communities in need of environmental and
community interventions.
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Currently there are no identified primary preventive measures that can be used to
prevent the effects of chronic low-level lead exposure in the pediatric brain. Research at the
molecular level needs to continue to identify affected pathways or targets for preventive
measures. The current study identified both pro- and anti-inflammation markers that are
affected by chronic low-level lead exposure. The results observed in this study can be used to
further investigate the specific neuroinflammatory mechanisms affecting normal brain
development and/or function.
Conclusion
The brain is a highly complex organ requiring a homeostatic environment to function
normally. During neurodevelopment, cytokines are involved in the normal restructuring of the
brain by inducing programmed cell death as neuronal function becomes specialized (Victorio,
Havton, & Oliveira, 2010). The findings in the present study suggested that chronic exposure to
low levels of lead elicited an abnormal expression of a number of cytokines and biological
markers of inflammation. The abnormal expression of cytokines and pro- and antiinflammatory cytokines in the central nervous system have often been referred to as a doubleedged sword, as it can be both protective and deleterious to the brain (Victorio, Havton, &
Oliveira, 2010; Hu & Ivashkiv, 2009; Pang, L.W, Zheng, Cai, & Rhodes, 2006).
Previous studies have suggested that low-level lead exposures cause cognitive,
behavioral, and motor dysfunctions in children (Bellinger, Stiles, & Needleman, 1992; Canfield,
et al., 2003; Chiodo, Jacobson, & Jacobson, 2004; Lanphear, et al., 2005; Lanphear, Dietrich,
Auinger, & Cox, 2000; Nevin, 2009). Environmental interventions such as soil remediation can
significantly reduce environmental lead (Mielke, et al., 2010), however, because there may be
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no safe threshold for lead exposure, primary preventive methods are required. In order to
develop these measures, a better understanding of the molecular mechanisms activated by
lead is key. The mouse models in this study provided an insight to innate immune responses to
low levels of lead in the brain which may be presented similarly in human children. The study
results suggest that the expression of cytokines is altered in the brain exposed to low levels of
lead. These findings provide areas of further research that can assist in identifying targets for
primary preventive measures. As this is one of the first studies to observe the expression of
pro-/anti-inflammatory cytokines in brains of mice exposed to chronic low-level lead, further
studies need to be conducted to support these findings. Future studies should be conducted to
determine whether the genetic expression of markers observed is expressed similarly in
antibody and protein levels through the use of enzyme-linked immunosorbent assay (ELISA)
methodologies.
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TABLES
Table 1: cDNA Synthesis Master Mix
Component

Volume (μL)

10X RT Buffer

2.0

25X dNTP Mix (100 mM)

0.8

10X RT Random Primers

2.0

MultiScribeTM Reverse Transcriptase

1.0

RNase Inhibitor

1.0

Nuclease-free water

3.2

Total

10
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Table 2: cDNA Synthesis Thermal Cycler Program
Step 1

Step 2

Step 3

Step 4

Temperature

25oC

37oC

85oC

4o C

Time

10 minutes

120 minutes

5 minutes

∞
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Table 3: TaqMan® Probes for Brain Studies
Gene

GRP78

iNOS
Hmox-1
IL-6
IL-10
INF-γ
TNF-α

β-actin

Endogenous
control

Probe design is based on following Mus musculus sequences:
BC050927.1, AJ002387.1, AK004578.1, AK076079.1, AK077463.1,
AK144650.1, AK144742.1, AK146647.1, AK148539.1, AK149447.1,
AK151244.1, AK151647.1, AK151806.1, AK152020.1, AK152521.1,
AK152958.1, AK159719.1, AK160821.1, AK166739.1, AK167011.1,
AK168012.1, AK169034.1, AK192496.1, AK195133.1, AK197130.1,
AK200033.1, AK219322.1, BC005785.1, BG076621.2, D78645.1,
NM_022310.2, NM_022310.2, U89425.1
BC062378.1, AF065919.1, AF065920.1, AF065921.2, AF065922.2,
AF065923.2, AY090567.1, M84373.1, M87039.1, M92649.1,
NM_010927.1, NM_010927.1, NM_010927.1, U43428.1
BC010757.1, AK150934.1, AK151012.1, AK151627.1, AK153420.1,
AK153516.1, AK154598.1, AK159521.1, AK169227.1, M33203.1,
NM_010442.1, NM_010442.1, X13356.1
NM_031168.1, AK089780.1, AK150440.1, AK152189.1, J03783.1,
X06203.1, X54542.1
BC120612.1, M37897.1, NM_010548.1, NM_010548.1
BC119063.1, AK089574.1, AY423847.1, BC119065.1, K00083.1,
M28621.1, NM_008337.1, NM_008337.1, NM_008337.1
BC117057.1, AK153319.1, AK153800.1, AK154223.1, AK155964.1,
AY423855.1, M11731.1, M13049.1, NM_013693.1, NM_013693.1,
X02611.1

NM_007393.1, AK078935.1, AK088691.1, AK145191.1,
AK145196.1, AK145308.1, AK147787.1, AK149920.1,
AK150545.1, AK150553.1, AK150558.1, AK150570.1,
AK150662.1, AK150675.1, AK150711.1, AK150879.1,
AK151010.1, AK151136.1, AK151145.1, AK151159.1,
AK151166.1, AK151190.1, AK151202.1, AK151226.1,
AK151277.1, AK151297.1, AK151350.1, AK151386.1,
AK151398.1, AK151444.1, AK151468.1, AK151663.1,
AK151712.1, AK151898.1, AK151956.1, AK151995.1,
AK151999.1, AK152043.1, AK152052.1, AK152083.1,
AK152218.1, AK152433.1, AK152470.1, AK152591.1,
AK152615.1, AK152651.1, AK152671.1, AK152813.1,
AK152841.1, AK153461.1, AK159759.1, AK159834.1,
AK160029.1, AK166349.1, AK166498.1, AK167117.1,
AK167825.1, AK167960.1, AW537707.1, BC040513.1,
BG063688.2, BG063722.2, BG063855.2, J04181.1, M12481.1,
NM_007393.1, NM_007393.1, X03672.1, X03765.1

All TaqMan® Probes used the FAMTM reporter dye.
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TaqMan® Probe
Assay ID

Mm00517691_m1

Mm01309901_m1
Mm00516007_m1
Mm00446191_m1
Mm00439616_m1
Mm00801778_m1
Mm00443258_m1

Mm00607939_s1

Table 4: qRT-PCR Thermal Cycler Program
Cycle 1 (1 repeat) Cycle 2 (1 repeat)
Step 1
Step 1
Temperature
Time

500C
2 minutes

950C
10 minutes
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Cycle 3 (40 repeats)
Step 2
(Data Collection)
0
95 C
600C
15 seconds
60 seconds
Step 1

Table 5: Study 1 - Mean Expression of Markers

Anterior

Posterior

Control
Std Dev
Low Dose
Std Dev
High Dose
Std Dev
Control
Std Dev
Low Dose
Std Dev
High Dose
Std Dev

TNF-α

IL-6

IFN-γ

Hmox-1

iNOS*

IL-10*

GRP78

2.958E-02
7.985E-03
2.403E-02
2.108E-02
4.250E-02
3.065E-03
4.850E-02
1.354E-02
4.790E-02
2.119E-02
5.972E-02
6.206E-03

2.233E-02
2.580E-03
2.535E-02
4.572E-03
1.627E-02
3.935E-03
1.887E-02
1.886E-03
1.465E-02
6.662E-03
9.570E-03
1.477E-03

2.212E-04
6.127E-05
2.628E-04
1.270E-04
2.321E-04
7.272E-05
1.815E-04
6.905E-05
2.924E-04
1.471E-04
2.579E-04
1.643E-04

4.764
1.784
6.272
1.551
6.477
1.151
5.258
2.792
9.066
2.192
6.735
3.634

0.15011
0.02995
0.15364
0.03663
0.14039
0.00828
0.16477
0.03206
0.12769
0.04290
0.19864
0.04045

2.079E-03
5.239E-04
2.587E-03
1.651E-04
1.420E-03
1.794E-04
2.509E-03
4.690E-04
2.109E-03
8.140E-04
2.941E-03
8.893E-04

219.77
84.47
295.68
106.39
281.49
144.68
353.84
95.83
356.35
206.30
432.08
124.20

* Significant Brain Portion x Lead Exposure interaction
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Table 6: Study 2 - Mean Expression of Markers
TNF-α*
IL-6
Control
1.985E-02 1.556E-02
Std Dev
5.069E-03 4.227E-03
Low Dose 3.991E-02 1.333E-02
Anterior
Std Dev
3.448E-03 1.327E-03
High Dose 2.196E-02 1.455E-02
Std Dev
5.657E-03 1.812E-03
Control
2.113E-02 1.396E-02
Std Dev
1.729E-03 6.481E-03
Low Dose 2.973E-02 1.086E-02
Posterior
Std Dev
4.821E-03 2.223E-03
High Dose 2.564E-02 1.320E-02
Std Dev
4.182E-03 1.198E-03
Control
2.500E-02 1.083E-02
Std Dev
4.054E-03 3.724E-03
Low Dose 2.925E-02 7.960E-03
Cerebellum
Std Dev
5.986E-03 1.108E-03
High Dose 2.406E-02 7.426E-03
Std Dev
8.024E-03 1.201E-03
* Significant Brain Portion x Lead Exposure interaction
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IFN-γ
8.63E-05
4.41E-05
1.94E-04
8.00E-05
1.96E-04
3.59E-05
1.85E-04
3.56E-05
2.20E-04
8.00E-05
1.88E-04
4.56E-05
2.06E-04
7.46E-05
3.69E-04
3.04E-05
3.21E-04
9.00E-05

Hmox-1*
4.5634
1.0044
10.8736
0.6676
5.6164
1.5942
4.8003
2.4964
6.5778
1.0942
5.1386
0.6682
7.1416
1.4074
7.7071
0.7707
6.0895
1.9565

iNOS
0.08937
0.06388
0.06261
0.03142
0.10343
0.03244
0.09731
0.03382
0.11612
0.02028
0.15667
0.02656

IL-10
1.498E-03
2.992E-04
1.663E-03
6.842E-04
2.108E-03
7.129E-04
1.637E-03
4.181E-04
2.269E-03
7.863E-05
2.659E-03
2.388E-04

GRP78*
187.46
25.89
109.45
53.56
158.18
45.80
259.12
68.78
270.63
15.84
372.51
59.22

Cerebellum not considered for
iNOS, IL-10 and GRP 78 due to
the reduction of sample size
caused during the statistical
analysis if cerebellum were
considered.

FIGURES
Figure 1: Genetic Expression of TNF-α in Young Adult C57BL/6J Mice
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Error bars represent 95% Confidence Intervals.
*A significant difference was observed between the low dose group and the control group. The low
dose group was also statistically different from the high dose group.
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Figure 2: Genetic Expression of Hmox-1 in Young Adult C57BL/6J Mice
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Error bars represent 95% Confidence Intervals.
*A significant difference was observed between the low dose group and the control group. The low
dose group was also statistically different from the high dose group.
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Figure 3: Genetic Expression of GRP78 in Young Adult C57BL/6J Mice
450.00

Mean Relative Genetic Expression (ΔCT)

400.00

*

350.00
300.00

*

250.00
200.00

*

150.00
100.00

*

50.00
0.00

Anterior

Posterior

Control

187.46

259.12

Low Dose

109.45

270.63

High Dose

158.18

372.51

Error bars represent 95% Confidence Intervals.
*Significant difference observed between low dose and high dose groups.
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